News | November 03, 2021
Venus Remedies H1 net profit rises 315%
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Key takeaways of recent quarter & conference call highlights
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
Second interchangeable biosimilar product approved by agency
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Subscribe To Our Newsletter & Stay Updated
